Cytori Therapeutics Completes Development Of The Celution(TM) System

San Diego, CA - Cytori Therapeutics, Inc. recently announced it has completed the development of its Celution(TM) System for the isolation and concentration of adipose stem cells and will submit CE Mark application seeking approval for the system in Europe.

"The completion of the development and testing of our Celution(TM) System represents an important achievement," stated Christopher J. Calhoun, Chief Executive Officer for Cytori Therapeutics. "With this progress, we are now submitting our CE Mark application for regulatory approval in Europe. This is an important milestone that will position us to initiate clinical studies using adipose stem cells in Europe in 2006."

The Celution(TM) System will extract and concentrate a significant number of stem and regenerative cells from adipose tissue harvested by a physician in a simple liposuction procedure. The cells can then be administered to the same patient where tissue repair or regeneration is needed. Due to the abundance of stem cells residing in adipose tissue, external cell manufacturing or cell culture is not required to multiply an otherwise very rare cell population. Cytori's proprietary technology allows for a real-time process wherein a patient can receive their own regenerative cells in about an hour. By utilizing the patient's own cells, the need to use embryonic stem cells and cells from other donors is avoided. SOURCE: Cytori Therapeutics